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Other names: PKBBETA (PKB beta); PKBB (protein 
kinase B, beta); RAC-PK-Beta (rac protein kinase beta) 
Location: 19q13.2 
Note: Details concerning the local order of the human  
AKT2 locus can be found at ensembl.org. Human 
AKT2 is found in chromosome 19, position 
45,428,706-45,483,107. < or > symbols indicate the 
orientation of the genes. M3K10 is Mitogen-activated 
protein kinase kinase kinase 10 gene. CNTD2 is a gene 
encoding Cyclin N-terminal domain-containing protein. 




Genomic organization of human AKT2. Open boxes indicate untranslated regions and shaded boxes indicate coding regions of the 
gene. The ATG transcription start site is located in exon 2 and the TGA termination codon is located in exon 14. 
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AKT proteins contain an amino terminal pleckstrin homology (PH) domain, followed by a short helical region and kinase domain that 
terminates in a regulatory hydrophobic motif. Activation of AKT kinases is a multi-step process that involves both membrane 
translocation and phosphorylation. AKT activation occurs by means of stimulation of the growth factor receptor-associated 
phosphatidylinositol 3-kinase (PI3K). PI3K generates 3'-phosphorylated phosphoinositides, i.e., phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) and phosphatidylinositol-3,4-bisphosphate (PIP2) at the plasma membrane. Both phospholipids bind with high affinity to the PH 
domain, mediating membrane translocation of AKT. At the membrane, AKT2 is phosphorylated at two sites, threonine 309 (T309) and 
serine 474 (S474). 
Description 
The entire gene is about 54.4 Kb and contains 14 
exons. The open reading frame of the coding region is 
1,445 bp. 
Transcription 
Transcript length: 4,623 bp. 
Pseudogene 
No human pseudogene known. A mouse Akt2 
pseudogene was cloned and mapped to proximal mouse 
chromosome 11 by fluorescence in situ hybridization. 
Protein 
Description 
AKT2 protein consists of 481 amino acids, with a 
molecular weight of 55,769 Da. 
Expression 
Found in all human cell types so far analyzed; insulin 
responsive tissues such as normal brown fat, skeletal 
muscle and liver exhibit the highest expression levels 
of AKT2/Akt2. 
Localisation 
Predominantly cytoplasmic; also found at the plasma 
membrane and in the nucleus following its activation. 
Function 
AKT proteins mediate a variety of cellular functions, 
ranging from control of cell proliferation and survival 
to modulation of intermediary metabolism and 
angiogenesis. Such pleiotropic effects are the 
consequence of phosphorylation of numerous 
substrates, some of which are listed below. Most 
substrates share the consensus sequence for AKT 
phosphorylation, RXRXXS/T. For example, activated 
AKT exerts anti-apoptotic activity in part by preventing 
the release of cytochrome c from mitochondria, and 
phosphorylating and inactivating the pro-apoptotic 
factors BAD and pro-caspase-9. AKT also activates 
IkappaB kinase (IKK), a positive regulator of NF-
kappaB, which results in the transcription of anti-
apoptotic genes. AKT phosphorylates and inactivates 
FOXO transcription factors, which mediate the 
expression of genes critical for apoptosis, such as the 
Fas ligand gene. 
AKT activation mediates cell cycle progression by 
phosphorylation and inhibition of glycogen synthase 
kinase 3 beta to inhibit cyclin D1 degradation. AKT 
phosphorylates the cell cycle inhibitors p21WAF1 and 
p27Kip1 near the nuclear localization signal to induce 
cytoplasmic retention of these cell cycle inhibitors. 
Moreover, phosphorylation of AKT kinases also results 
in increased translation of cyclin D1, D3 and E 
transcripts. 
AKT activates the downstream mTOR kinase by 
inhibiting a complex formed by the tumor suppressor 
proteins TSC1 and TSC2, also known as hamartin and 
tuberin, respectively. mTOR broadly mediates cell 
growth and proliferation by regulating ribosomal 
biogenesis and protein translation and can regulate 
response to nutrients by restricting cell cycle 
progression in the presence of suboptimal growth 
conditions. 
AKT signaling also contributes to other cellular 
processes considered to be cancer hallmarks. AKT 
promotes the phosphorylation and translocation of 
Mdm2 into the nucleus, where it downregulates p53 
and thereby antagonizes p53-mediated cell cycle 
checkpoints. AKT signaling is linked to tumor cell 
migration, and it contributes to tumor invasion and 
metastasis by promoting the secretion of matrix 
metalloproteinases. Moreover, vascular endothelial 
growth factor (VEGF) effects on cell survival have 
been shown to be mediated by the Flk1/VEGFR2 -
PI3K-AKT pathway. In other cellular processes, AKT 
has been shown to phosphorylate human telomerase 
reverse transcriptase (hTERT), thereby stimulating 
telomerase activity and replication. Collectively, these 
findings implicate up-regulation of the AKT pathway 
in many aspects of tumorigenesis. 
Homology 
All three AKT kinases belong to the more general class 
of AGC kinases (related to AMP/GMP kinase and 
protein kinase C). The kinase domain of AKT shares 
high similarity with other members of the AGC family 
of kinases such as PKA, PKC, p70 S6K, and p90 RSK. 
The sequence identities among the three AKTs in the 
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kinase domain exceed 87%. The three AKT kinases are 
identical in the ATP binding region, except for one 
residue: Ala 230 of AKT1 is conserved in AKT2 (Ala 
232), but switches to Val 228 in AKT3. In addition, 
each of the three AKT kinases has a carboxy terminal 
extension of about 40 amino acids. 
Human AKT2 is 98.1% similar to M. musculus Akt2; 
97.7% similar to the R. norvegicus homolog; 61.3% 
similar to D. melanogaster protein kinase RAC; 52.4% 
similar to C. elegans Akt/PKB serine/threonine kinase; 




Insulin resistance and a diabetes mellitus-like syndrome 
have been described in knockout mice lacking Akt2. 
Somatic 
Individuals carrying a G-to-A transition in the AKT2 
gene resulting in an Arg-to-His substitution at codon 
274 (R274H) were found to be markedly 
hyperinsulinemic. However, a large case-control study 
showed that variation in and around the AKT2 locus is 
unlikely to contribute significantly to increased risk of 
type 2 diabetes. 
Mutations in AKT2 are uncommon in human tumors. 
For example, AKT2 mutations have been reported in 1 
of 51 gastric carcinomas and 2 of 79 lung carcinomas. 
The mutations consisted of one missense mutation and 




Frequent activation of AKT has been reported in a 
broad range of human cancers including various 
carcinomas, glioblastoma multiforme, and 
hematological malignancies. In some of these tumor 
types, AKT activation has been shown to correlate with 
advanced disease and/or poor prognosis. AKT is a 
major mediator of survival signals that protect cells 
from undergoing apoptosis and, thus, is a potentially 
important therapeutic target. Ovarian cancer cell lines 
with either constitutive AKT1 activity or AKT2 gene 
amplification have been shown to be highly resistant to 
paclitaxel compared to cells with low AKT levels. 
Oncogenesis 
In 1992, amplification and overexpression of AKT2 
was reported in a subset of ovarian carcinomas. AKT2 
was shown to be amplified and overexpressed in 2 of 8 
ovarian carcinoma cell lines and 2 of 15 primary 
ovarian tumors. Recently, amplification of AKT2 was 
found in 18.2% of high-grade ovarian carcinomas. 
Amplification and/or overexpression of AKT2 was 
reported in 10-20% of primary pancreatic carcinomas 
and pancreatic cancer cell lines. PANC1 and ASPC1 
cell lines exhibited 30-fold and 50-fold amplification of 
AKT2, respectively, and highly elevated levels of 
AKT2 RNA and protein. As an early indication of the 
potential importance of molecularly targeting the AKT 
pathway, AKT2 expression and tumorigenicity of 
PANC1 cells in nude mice was markedly inhibited by 
transfection with an antisense AKT2 construct but not 
with a control AKT2 construct in the sense orientation. 
Through the use of in vitro kinase assays, activation of 
the AKT2 kinase has been observed in about 40% of 
ovarian and pancreatic cancers. 
 
Hyperactivation of AKT kinases have been reported in a wide 
assortment of human solid tumors and hematological 
malignancies. Activation of growth factor receptors either by 
ligand stimulation or receptor overexpression/mutation is one 
of the mechanisms leading to the upregulation of AKT 
signaling. Other mechanisms include activation of oncoproteins 
and inactivation of tumor suppressors intersecting the AKT 
signal transduction pathway. AKT is now known to be a central 
player in a signaling pathway consisting of many components 
that have been implicated in tumorigenesis, including upstream 
phosphatidylinositol 3-kinase (PI3K) and PTEN (Phosphatase 
and Tensin homologue deleted on chromosome Ten). Several 
proteins, such as AKT, eIF4E, and the subunits of PI3K, can 
act as oncoproteins when activated or overexpressed. 
Germline mutations in PTEN, LKB1, TSC2/TSC1, and VHL are 
linked with different dominantly-inherited cancer syndromes. 
Each of these tumor suppressors is a negative regulator of the 
AKT pathway which, when deregulated, results in altered 
translation of cancer-related mRNAs that regulate cellular 
processes such as cell cycle progression, growth, cell survival, 
invasion, and communication with the extracellular 
environment. 
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